A limited autoimmunity to p185neu elicited by DNA and allogeneic cell vaccine hampers the progression of preneoplastic lesions in Her-2/neu transgenic mice

International Journal of Immunopathology and Pharmacology

Volumn 18, Issue 2, 2005, Pages 351-363

  Iacono, M Lo ^a   Cavallo, Federica ^a,e   Quaglino, E ^a   Rolla, S ^a   Iezzi, M ^b   Pupa, S M ^c   De Giovanni, C ^f   Lollini, P L ^d   Musiani, P ^b   Forni, G ^a   Calogero, R A ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e SAN LUIGI GONZAGA HOSPITAL   (Italy)

^f NONE

Author keywords

Allogeneic vaccine; DNA vaccination; Her 2 neu; Immunoprevention; Mammary carcinogenesis

Indexed keywords

ALLOANTIGEN; CANCER CELL VACCINE; CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PLASMID DNA; PROTEIN P185; PROTEIN P185NEU; UNCLASSIFIED DRUG; DNA VACCINE; ERBB2 PROTEIN, RAT; GLYCOPROTEIN;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CONTROLLED STUDY; CYTOKINE RELEASE; DNA MICROARRAY; FEMALE; FOLLOW UP; GENE EXPRESSION; INVASIVE CARCINOMA; MOUSE; NONHUMAN; PRECANCER; PRIORITY JOURNAL; PROTECTION; PROTEIN DOMAIN; TIME; TRANSGENIC MOUSE; VACCINATION; ANIMAL; DRUG EFFECT; EXPERIMENTAL NEOPLASM; GENETICS; IMMUNOLOGY; MOLECULAR CLONING; PATHOLOGY; RAT; TRANSGENE; TUMOR CELL LINE;

ANIMALS; AUTOIMMUNITY; CELL LINE, TUMOR; CLONING, MOLECULAR; FEMALE; GLYCOPROTEINS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; PRECANCEROUS CONDITIONS; RATS; RECEPTOR, ERBB-2; TRANSGENES; VACCINES, DNA;

EID: 20444432319     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200501800217     Document Type: Article

References (43)

1. Rovero S., A. Amici, E, Di Carlo, R. Bei, P. Nanni, E. Quaglino, P. Porcedda, K. Boggio, A. Smorlesi, P.-L. Lollini, L. Landuzzi, M.P. Colombo, M. Giovarelli, P. Musiani and G. Forni. 2000. DNA vaccination against rat Her-2/neu p 185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J. Immunol. 165:5133.
2. Nanni P., G. Nicoletti, C. De Giovanni, L. Landuzzi, E. Di Carlo, F. Cavallo, S. M. Pupa, I. Rossi, M.P. Colombo, C. Ricci, A. Astolfi, P. Musiani, G. Forni and P.-L. Lollini. 2001. Combined allogeneic tumor cell vaccination and systemic IL-12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J. Exp. Med. 194:1195.
3. Cappello P., F. Triebel, M. Iezzi, C. Caorsi, E. Quaglino, P. Nanni, A. Amici, E. Di Carlo, P. Musiani, M. Giovarelli and G. Forni. 2003. LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. Cancer Res. 63:2518.
4. Quaglino E., S, Rolla, M, Iezzi, M. Spadaro, P. Musiani, C. De Giovanni, P.-L. Lollini, S. Lanzardo. G. Forni, R. Sanges, S. Crispi, P. De Luca, R. Calogero and F. Cavallo. 2004. Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. J. Clin. Invest. 113:709.
5. Quaglino E., M. Iezzi, C. Mastini, A. Amici, F. Pericle, E. Di Carlo, S.M. Pupa, C. De Giovanni, M. Spadaro, C. Curcio, P.-L. Lollini, P. Musiani, G. Forni and F. Cavallo. 2004. Electroporated DNA vaccine clears away multifocal mammary carcinomas in Her-2/neu transgenic mice. Cancer Res. 64:2858.
6. Forni G., P.-L. Lollini, P. Musiani and M. P. Colombo. 2000. Immunoprevention of cancer: Is the time ripe? Cancer Res. 60:2571.
7. Lollini P.-L. and G. Forni. 2002. Antitumor vaccines: Is it possible to prevent a tumor? Cancer Immunol. Immother. 51:409.
8. Finn O. J. and G. Forni. 2002. Propylactic cancer vaccines. Curr. Opin. Immunol. 14:172.
9. Lollini P.-L. and G. Forni. 2003. Cancer immunoprevention: Tracking down persistent tumor antigens. Trends Immunol. 24:62.
10. Finn O. J. 2003. Premalignant lesions as target for cancer vaccines. J. Exp. Med. 198:1623.
11. Lollini P.-L., C. De Giovanni, G. Nicoletti, E. Di Carlo, P. Musiani, P. Nanni and G. Forni, 2002. Immunoprevention of Colorectal Cancer: A Future Possibility? Gastroenterol. Clin. North. Am. 31:1001.
12. Nanni P., S. M. Pupa, G. Nicoletti, C. De Giovanni, L. Landuzzi, I. Rossi, A. Astolfi, C. Ricci, R. De Vecchi, A. M. Invernizzi, E. Di Carlo, P. Musiani, G. Forni, S. Menard and P.-L. Lollini. 2000. p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. Int. J. Cancer 87:186.
13. Muller W. J., E. Sinn, R. Wallace, P. K. Pattengale and P. Leder. 1988. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54:105.
14. Xu R., M. A. Perle, G. Inghirami, W. Chan, Y. Delgado and H. Feiner. 2002. Amplification of Her-2/neu gene in Her-2/neu -overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archivial material. Mod. Pathol. 15:116.
15. Di Carlo E., M. G. Diodoro, K. Boggio, A. Modesti, M. Modesti, P. Nanni, G. Forni and P. Musiani. 1999. Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. Lab. Invest. 79:1261.
16. Jones F. E. and D. F. Stern. 1999. Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobulo alveolar development and lactation. Oncogene 18:3481.
17. Disis M. L., E. Calenoff, G. McLaughlin, A. E. Murphy, W. Chen, B. Groner, M. Jeschke, N. Lydon, E. McGlynn and R. B. Livingston. 1994. Existent T-cells and antibodies immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. 54:16.
18. Rentzsch C., S. Kayser, S. Stumm, I. Watermann, S. Walter, S. Stevanovic, D. Wallwiener and B. Guckel. 2003. Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells. Clin. Cancer Res. 9:4376.
19. Shawver L. K., D. Slamon and A. Ullrich. 2002. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1:117.
20. Boggio K., G. Nicoletti, E. Di Carlo, F. Cavallo, L. Landuzzi, C. Melani, M. Giovarelli, I. Rossi, P. Nanni, C. De Giovanni, C. Bouchard, S. Wolf, A. Modesti, P. Musiani, P-L. Lollini, M. P. Colombo and G. Forni. 1998. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J. Exp. Med. 188:589.
21. Lollini P-L., G. Nicoletti, L. Landuzzi, C. De Giovanni, I. Rossi, E. Di Carlo, P. Musiani, W. J. Muller and P. Nanni. 1998. Down regulation of major histocompatibility complex class I expression in mammary carcinoma of Her-2 transgenic mice. Int. J. Cancer 77:937.
22. Lollini P-L., M. C. Bosco, F. Cavallo, C. De Giovanni, M. Giovarelli, L. Landuzzi, P. Musiani, A. Modesti, G. Nicoletti, G. Palmieri, et al. 1993. Inhibition of tumor growth and enhancement of metastasis after transfection of the gamma-interferon gene. Int. J. Cancer 55:320.
23. Piechocki M. P., S. A. Pilon and W.-Z. Wei. 2001. Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2. J. Immunol. 167:3367.
24. Rovero S., K. Boggio, E. Di Carlo, A. Amici, E. Quaglino, P. Porcedda, P. Musiani and G. Forni. 2001. Insertion of the DNA for the 163-171 peptide of il1b enables a dna vaccine encoding p185neu to inhibit mammary carcinogenesis in HER-2/neu transgenic BALB/C mice. Gene Therapy 8:447.
25. Wu Z. and R.A. Irizarry. 2004. Preprocessing of oligonucleotide array data. Nat. Biotechnol. 22:656
26. Li C. and W. H. Wong. 2001. Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection. Proc. Natl. Acad. Sci. USA. 98:31.
27. Tusher V.G., R. Tibshirani and G. Chu. 2001. Significance analysis of microarrays applied to the ionising radiation response. Proc. Natl. Acad. Sci. USA. 98:5116.
28. Ashburner M., C. A. Ball, J. A. Blake, D. Botstein, H. Butler, J. M. Cherry, A. P. Davis, K. Dolinski, S. S. Dwight, J. T. Eppig, M. A. Harris, D. P. Hill, L. Issel-Tarver, A. Kasarskis, S. Lewis, J. C. Matese, J. E. Richardson, M. Ringwald, G. M. Rubin and G. Sherlock. 2000. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 25:25.
29. Hosack D. A., G. Jr. Dennis, B. T. Sherman, H. C. Lane and R. A. Lempicki. 2003. Identifying Biological Themes within Lists of Genes with EASE. Genome Biology 4:70.
30. Blume-Jensen P. and T. Hunter. 2001. Oncogenic kinase signalling. Nature 411:355.
31. Katsumata M., T. Okudaira, A. Samanta, D. P. Clark, J. A. Drebin, P. Jolicoeur and M. I. Greene. 1995. Prevention of breast tumour development in vivo by downregulation of the p185neu receptor. Nat. Med. 1:644.
32. Klapper L. N., N. Vaisman, E. Hurwitz, R. Pinkas-Kramarski, Y. Yarden and M. Sela. 1997. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene 14:2099.
33. Di Carlo E., S. Rovero, K. Boggio, E. Quaglino, A. Amici, A. Smorlesi, G. Forni and P. Musiani. 2001. Inhibition of mammary carcinogenesis by systemic IL-12 or p185neu DNA vaccination in Her-2/neu transgenic BALB/c mice. Clin. Cancer Res. 7:830.
34. Fabre J. W. 2001. The allogeneic response and tumor immunity. Nat. Med. 6:649.
35. Musiani P., A. Modesti, M. Giovarelli, F. Cavallo, M. P. Colombo, P.-L. Lollini and G. Forni. 1997. Cytokines, tumour-cell death and immunogenicity: a question of choice. Immunol. Today 18:32.
36. Bowne W. B., R. Srinivasan, J. D. Wolchok, W. G. Hawkins, N. E. Blachere, R. Dyall, J. J. Lewis and A. N. Houghton. 1999. Coupling and uncoupling of tumor immunity and autoimmunity. J. Exp. Med. 190:1717.
37. Pardoll D.M. 1999. Inducing autoimmune disease to treat cancer. Proc. Natl. Acad. Sci. USA 96:5340.
38. Bogdanos D. P., M. Lenzi, M. Okamoto, E.I. Rigopoulou, P. Muratori, Y. Ma, L. Muratori, D. Tsantoulas, G. Mieli-Vergani, F.B. Bianchi and D. Vergani. 2004. Multiple viral/self immunological cross-reactivity in liver kidney microsomal antibody positive hepatitis C virus infected patients is associated with the possession of HLA b51. Int. J. Immunopathol. Pharmacol. 17:83.
39. Vojdani A., J. B. Pangborn, E. Vojdani and E.L. Cooper. 2003. Infections, toxic chemicals and dietary peptides binding to lymphocyte receptors and tissue enzymes are major instigators of autoimmunity in autism. Int. J. Immunopathol. Pharmacol. 16:189
40. Cross M.L. 2004. Immune-signalling by orally-delivered probiotic bacteria: effects on common mucosal immunoresponses and protection at distal mucosal sites. Int. J. Immunopathol. Pharmacol. 17:127
41. Reilly R. T., L. A. Emens and E. M. Jaffee. 2001. Humoral and cellular immune responses: independent forces or collaborators in the fight against cancer? Curr. Opin. Investig. Drugs. 2:133.
42. Lorusso L., I.K. Hart, B. Giometto, R. Pezzani, J.C. Broome, D. Gritti, C. Gasparetto and G. Ricevuti. 2004. Immunological features of neurological paraneoplastic syndromes. Int. J. Immunopathol. Pharmacol. 17:135
43. Di Pietro R., L. Centurione, N. Sabatini, D. Bosco, S. Sancilio, F. Garaci, R. Rana and A. Cataldi. 2004. Caspase-3 is dually regulated by apoptogenic factors mitochondrial release and by SAPK/JNK metabolic pathway in leukemic cells exposed to etoposide-ionizing radiation combined treatment. Int. J. Immunopathol. Pharmacol. 17:181.